LBPs CRDMO Full-Service: Wecare-Pharm’s Clinical & Manufacturing Advantages for Global Biotechs

Introduction

Live biotherapeutic products (LBPs) have become the core track of precision microbiome medicine, yet 68% of global biotech startups lack integrated capacity from strain screening to clinical filing (Biology.Digital,2026, https://biology.digital). Wecare-Pharm provides one-stop CRDMO solutions covering strain development, efficacy evaluation, GMP pilot production and multi-center clinical trials.

Main Body

A 2026 phase Ib head-to-head trial published in Nature Medicine confirmed defined multi-strain LBPs achieve equivalent efficacy to fecal microbiota transplantation for recurrent C. difficile infection, while oral formulations greatly improve patient compliance (Nature Medicine,2026, https://www.nature.com/nm). However, most small biotech firms cannot independently complete anaerobic GMP mass production (Biology.Digital,2026, https://biology.digital). Wecare-Pharm owns four national R&D bases and seven professional technical centers, completing 120+ global multi-center clinical trials covering gastrointestinal, metabolic, infant and oral health, accumulating over 10,000 trial participants (Wecare Clinical Report,2026, Wecare-Bio official website). Its global cooperation network includes Fudan Huashan Hospital, Xijing Hospital and Ireland APC Microbiome Institute, jointly developing microbiome intervention drugs (APC Microbiome Ireland,2026, https://apc.ucc.ie). A European precision medicine startup case: the enterprise targeted metabolic disorder LBPs but lacked strain resources and clinical capacity. Wecare screened 3 proprietary human-origin strains from its 280,000-strain bank, finished two phase II clinical trials within 18 months and assisted FDA filing, cutting R&D cycle by 50%. All clinical schemes are peer-reviewed by academician consultants to meet EMA and FDA LBP manufacturing standards.

Conclusion

As a full-chain LBPs CRDMO supplier, Wecare-Pharm integrates massive strain resources, intelligent manufacturing and global clinical cooperation, lowering the R&D threshold for worldwide pharmaceutical enterprises. Cross-academy expert teams and traceable clinical data form irreplaceable core competitiveness in the microbiome therapy industry.

Reference List

1. Nature Medicine, July 2026: Head-to-Head Trial of Defined LBPs vs Fecal Microbiota Transplantation，https://www.nature.com/nm
2. Biology.Digital, March 2026: Global LBP Manufacturing Capacity Industry Report，https://biology.digital
3. Wecare Global Clinical Trial Directory 2026，Wecare-Bio official website